Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:53:41.054Z.
Calculation as of: 2026-10-06T20:53:41.054Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 49ccfc7bc81d1e6c211e00ba0f17dd71ad394db50a55f8cf6fe3d6b4e4d88636
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$1.73B
Price/OCF Ratio
N/A
TTM Avg
11.30
3Y Avg
11.30
5Y Avg
11.30
Market Cap
$1.74B
Price/OCF Ratio
8.45
TTM Avg
22.76
3Y Avg
36.91
5Y Avg
32.83
Market Cap
$1.74B
Price/OCF Ratio
30.71
TTM Avg
60.51
3Y Avg
60.51
5Y Avg
60.51
Market Cap
$1.74B
Price/OCF Ratio
1166.80
TTM Avg
1290.99
3Y Avg
1290.99
5Y Avg
274.70
Market Cap
$1.75B
Price/OCF Ratio
6.80
TTM Avg
7.16
3Y Avg
10.90
5Y Avg
18.70
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | $1.70B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 5.35 | 9.21 | 10.96 | 12.42 |
| Personalis, Inc. (PSNL)vs › | $1.71B | N/A | 127.45 | 127.45 | 127.45 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | N/A | 11.30 | 11.30 | 11.30 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 8.45 | 22.76 | 36.91 | 32.83 |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | 30.71 | 60.51 | 60.51 | 60.51 |
| Absci Corporation (ABSI)vs › | $1.74B | N/A | N/A | N/A | N/A |
| Novocure Ltd (NVCR)vs › | $1.74B | 1166.80 | 1290.99 | 1290.99 | 274.70 |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 6.80 | 7.16 | 10.90 | 18.70 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
